News
Daiichi Sankyo grabs first approval for blood cancer drug Ez...
Japan's Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T